RP3: Clinical Trials

2 trials of RP3, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 terminated, 1 withdrawn. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Terminated 1, Withdrawn 1

Follow RP3: new trials by email Literature Review of RP3 trials Research Report on RP3

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel - Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 2WithdrawnReplimune, Inc.2024-01-302025-03-11
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
RP2, RP3, atezolizumab - Refractory Metastatic Colorectal Cancer, pMMR
Phase 2TerminatedReplimune, Inc.52023-06-292026-02-02

Conditions studied

Colorectal Neoplasms (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Sponsors

Replimune, Inc. (2)

Countries

United States (2)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Greece (1)  ·  Poland (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

David Cohan, MD/FACS (1)  ·  Gary Vanasse, MD (1)